Atgam: Marketed to treat of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation

In a long-term U.S. study in 122 patients, 55% of patients given Atgam plus cyclosporine were alive at 7 years. Data were published in the Journal of the American Medical Association. ...